Program
Iodine I 131 IPA
Also written as “TLX-101-Tx + Lomustine” and “131I-IPA”.
Its studies are mostly in Glioblastoma, led by Telix Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Telix Pharmaceuticals | 22 open or running | phase 3since Jul 17, 2025 | Apr 22, 2022 | Jun 2027phase 1 · NCT05450744 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 22, 2022First study: phase 1 study in NeoplasmsFirst studyNCT05450744 · 12 enrolled · Australia, Austria, Netherlands
- Jul 17, 2025Phase 3 study in NeoplasmsNCT07100730 · 51 planned · Australia, Austria, Belgium and more
- Nov 16, 2026Primary completion moved from 2027-07 to 2028-07Date moved laterphase 3 · +12 months · NCT07100730
Ahead
- Jun 2027Primary completion: phase 1 study in NeoplasmsNCT05450744
- Jul 2028Primary completion: phase 3 study in NeoplasmsNCT07100730
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07100730Neoplasms · Australia, Austria, Belgium and more | 3 | Recruiting | Jul 2028 | 51 |
| NCT05450744Neoplasms · Australia, Austria, Netherlands | 1 | Active, not recruiting | Jun 2027 | 12 |
How it is read
Names in the registry
- “TLX-101-Tx + Lomustine”, 1 entry
- “131I-IPA”, 1 entry
Conditions, from the studies’ own filings
- Glioblastoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.